ALLOX Raises $10.5M Seed for AI Drug Discovery Platform

Biotechnology firm ALLOX has successfully closed a significant $10.5 million seed funding round, signaling a major advancement in its mission to transform the drug discovery process. The capital infusion is earmarked for expanding its proprietary artificial intelligence-driven platform and accelerating the development of novel small-molecule therapeutics. This funding round saw robust participation from key investors, including lead investor Asabys via its Sabadell Asabys II fund, alongside contributions from CDTI through SICC Innvierte and the Institut Català de Finances (ICF).

ALLOX's innovative platform distinguishes itself by integrating high-throughput genetics, experimental biology, and sophisticated AI algorithms. This powerful combination allows the company to pinpoint previously intractable drug targets, particularly those involving protein-protein interactions and transcription factors. These targets have historically presented formidable challenges for conventional drug development methodologies due to their complex nature and difficulty in identifying suitable binding sites.

The company's unique approach involves meticulously measuring the impact of thousands of genetic mutations concurrently. This granular analysis enables the mapping of critical regions influencing protein structure and function. By identifying allosteric, orthosteric, and other regulatory sites, ALLOX can uncover potential binding pockets essential for designing highly targeted small-molecule drugs. This capability is crucial in a pharmaceutical market increasingly seeking precision medicines.

“Our strategy is to merge extensive functional data with predictive AI to unlock a wider spectrum of challenging drug targets,” stated Júlia Domingo, CEO and co-founder of ALLOX. “This will significantly expedite the discovery of truly differentiated small-molecule therapeutics, addressing unmet medical needs more effectively.” The company's ability to generate functional molecules, rather than just identifying potential binders, is a key differentiator in the competitive biotech funding environment.

In conjunction with the funding announcement, ALLOX has appointed Morten Graugaard as the Independent Chair of its Board of Directors. Graugaard brings over two decades of invaluable experience in life sciences investment, research and development, and business development, having held prominent roles at entities such as Orbis Medicines, Novo Holdings, and Lundbeck. His expertise is expected to guide ALLOX through its next phase of growth and platform enhancement.

The newly acquired capital will be instrumental in scaling the platform's capabilities, refining proprietary AI models for predicting therapeutic opportunities from large-scale biophysical datasets, and bolstering the internal drug discovery team. ALLOX also intends to advance its internal research programs towards a robust pipeline of proprietary small-molecule drug candidates and forge strategic research collaborations with leading pharmaceutical and biotechnology partners. This strategic expansion positions ALLOX to make significant contributions to the therapeutic development landscape.